LUMAKRAS ® (sotorasib) U.S. Indication LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as ...

fda approves lumakras® (sotorasib) in combination with vectibix® (panitumumab) for chemorefractory kras g12c-mutated metastatic colorectal cancer PR Newswire THOUSAND OAKS, Calif., Jan. 17, 2025 ...

LUMAKRAS® (sotorasib) U.S. Indication LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as ...

--Amgen today announced new combination study results from the Phase 1 b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of LUMAKRAS™, the ...

THOUSAND OAKS, Calif., Aug. 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Dru ...

Verastem Oncology has established clinical collaborations with Amgen and Mirati to evaluate LUMAKRAS™ (sotorasib) and KRAZATI™ (adagrasib) in combination with avutometinib in KRAS G12C mutant ...

An FDA advisory committee voted 10-2 that the results of a confirmatory trial for the targeted lung cancer drug sotorasib cannot be interpreted reliably.The trial showed sotorasib (Lumakras, Amgen ...

LUMAKRAS ® (sotorasib) Demonstrated Delayed Time to CNS Progression, Longer CNS PFS and Higher Intracranial ORR vs Docetaxel in Post-Hoc Analysis of Phase 3 CodeBreaK 200 Trial LUMAKRAS Shows ...

The US Food and Drug Administration (FDA) has approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for the treatment of certain adult patients with metastatic ...

Treating severe KRAS G12C-related arteriovenous malformations with sotorasib (Lumakras) appeared to be effective in a small French study.. Two adult patients with the life-threatening condition ...